Lake Street analyst Frank Takkinen reiterated a Buy rating on REPRO-MED Systems (KRMD – Research Report) today and set a price target of $5.00.

Launched in 2018, the Morningstar Minority Empowerment Index highlights companies that demonstrate a strong commitment to ...

Meet Verdoie, a new luxury Parisian beauty brand that puts mushrooms in the forefront of its formulas. This moisturizing ...

This story is part of NBC Select’s New & Notable column, where we highlight our favorite product launches. We will ...

Symbiq raises the bar for infusion pump technology with an innovative and user-centric approach. With its unique combination of nurse-friendly features, auto-default to safety software ...

Plasma-derived therapies are essential for treating a wide range of conditions, including immune deficiencies, bleeding ...

In addition, the company offers medical devices and machines, such as cardiovascular ultrasounds; needless connectors and IV lines; and ambulatory/PCA infusion pumps for critical care, anti ...

J.P. Morgan analyst David Adlington maintained a Buy rating on Fresenius SE & Co. KGaA (0OO9 – Research Report) today and set a price ...

Systems (NASDAQ: KRMD), a medical technology firm with a market capitalization of $194 million, announced a partnership with a global pharmaceutical manufacturer to conduct a Phase III clinical trial.

This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories ...